The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.
As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... 9% overall thanks to gains in the US, where it is sold as Rituxan, as well as international markets,
Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.
set a target of £300m in savings from biosimilars in the next three years – led by cheaper versions of drugs such as Herceptin, MabThera and Humira – but Warwick Smith says the
Roche has seen revenues from blockbuster MabThera/Rituxan slashed in half in Europe thanks to growing biosimilar competition in the second quarter.
Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates. Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment ... a significant increase in progression-free survival (PFS) compared
[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...